Back to Search Start Over

Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype.

Authors :
Anjema, Karen
Rijn, Margreet van
Hofstede, Floris C.
Bosch, Annet M.
Hollak, Carla E. M.
Rubio-Gozalbo, Estela
De Vries, Maaike C.
Janssen, Mirian C. H.
Boelen, Carolien C. A.
Burgerhof, Johannes G. M.
Blau, Nenad
Rebecca Heiner-Fokkema, M.
Van Spronsen, Francjan J.
Source :
Orphanet Journal of Rare Diseases; 2013, Vol. 8 Issue 1, p1-9, 9p, 2 Diagrams, 3 Charts, 1 Graph
Publication Year :
2013

Abstract

Background: How to efficiently diagnose tetrahydrobiopterin (BH4) responsiveness in patients with phenylketonuria remains unclear. This study investigated the positive predictive value (PPV) of the 48-hour BH4 loading test and the additional value of genotype. Methods: Data of the 48-hour BH4 loading test (20 mg BH4/kg/day) were collected at six Dutch university hospitals. Patients with ⩾30% phenylalanine reduction at ⩾1 time points during the 48 hours (potential responders) were invited for the BH4 extension phase, designed to establish true-positive BH4 responsiveness. This is defined as long-term ⩾30% reduction in mean phenylalanine concentration and/or ⩾4 g/day and/or ⩾50% increase of natural protein intake. Genotype was collected if available. Results: 177/183 patients successfully completed the 48-hour BH4 loading test. 80/177 were potential responders and 67/80 completed the BH4 extension phase. In 58/67 true-positive BH4 responsiveness was confirmed (PPV 87%). The genotype was available for 120/177 patients. 41/44 patients with ⩾1 mutation associated with long-term BH4 responsiveness showed potential BH4 responsiveness in the 48-hour test and 34/41 completed the BH4 extension phase. In 33/34 true-positive BH4 responsiveness was confirmed. 4/40 patients with two known putative null mutations were potential responders; 2/4 performed the BH4 extension phase but showed no true-positive BH4 responsiveness. Conclusions: The 48-hour BH4 loading test in combination with a classified genotype is a good parameter in predicting true-positive BH4 responsiveness. We propose assessing genotype first, particularly in the neonatal period. Patients with two known putative null mutations can be excluded from BH4 testing. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17501172
Volume :
8
Issue :
1
Database :
Complementary Index
Journal :
Orphanet Journal of Rare Diseases
Publication Type :
Academic Journal
Accession number :
89708780
Full Text :
https://doi.org/10.1186/1750-1172-8-103